- Home
- RNTX vs DTIL Comparison
RNTX vs DTIL Comparison
Compare RNTX & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNTX
- DTIL
- Stock Information
- Founded
- RNTX 2001
- DTIL 2006
- Country
- RNTX United States
- DTIL United States
- Employees
- RNTX N/A
- DTIL N/A
- Industry
- RNTX Biotechnology: Pharmaceutical Preparations
- DTIL Biotechnology: Pharmaceutical Preparations
- Sector
- RNTX Health Care
- DTIL Health Care
- Exchange
- RNTX Nasdaq
- DTIL Nasdaq
- Market Cap
- RNTX 44.2M
- DTIL 56.2M
- IPO Year
- RNTX N/A
- DTIL 2019
- Fundamental
- Price
- RNTX $1.72
- DTIL $5.15
- Analyst Decision
- RNTX
- DTIL Strong Buy
- Analyst Count
- RNTX 0
- DTIL 2
- Target Price
- RNTX N/A
- DTIL $47.00
- AVG Volume (30 Days)
- RNTX 27.4K
- DTIL 161.1K
- Earning Date
- RNTX 05-19-2025
- DTIL 05-15-2025
- Dividend Yield
- RNTX N/A
- DTIL N/A
- EPS Growth
- RNTX N/A
- DTIL N/A
- EPS
- RNTX N/A
- DTIL 1.04
- Revenue
- RNTX N/A
- DTIL $68,696,000.00
- Revenue This Year
- RNTX N/A
- DTIL N/A
- Revenue Next Year
- RNTX N/A
- DTIL $30.20
- P/E Ratio
- RNTX N/A
- DTIL $4.95
- Revenue Growth
- RNTX N/A
- DTIL 40.98
- 52 Week Low
- RNTX $1.35
- DTIL $3.61
- 52 Week High
- RNTX $4.40
- DTIL $13.44
- Technical
- Relative Strength Index (RSI)
- RNTX N/A
- DTIL 49.18
- Support Level
- RNTX N/A
- DTIL $5.08
- Resistance Level
- RNTX N/A
- DTIL $5.97
- Average True Range (ATR)
- RNTX 0.00
- DTIL 0.36
- MACD
- RNTX 0.00
- DTIL -0.02
- Stochastic Oscillator
- RNTX 0.00
- DTIL 19.61
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03, LTI-01, and others.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.